Company profile: Inozyme Pharma
1.1 - Company Overview
Company description
- Provider of therapies for rare diseases of calcification affecting soft tissues and bone, including a clinical-stage enzyme therapy (INZ-701) for pathologic mineralization and intimal proliferation in ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. Conducts clinical trials, offers a genetic testing process for ENPP1 Deficiency, and provides patient and family support and community resources.
Products and services
- Clinical Trials: Rare-disease-focused clinical programs conducted by Inozyme to evaluate potential treatments for ENPP1 Deficiency and ABCC6 Deficiency
- Genetic Testing Process: Diagnostic-grade workflow offered to identify ENPP1 Deficiency, supporting diagnosis and potential treatment eligibility for rare-disease clinical programs
- INZ-701: A clinical-stage enzyme therapy engineered to counter pathologic mineralization and intimal proliferation in ENPP1 Deficiency, ABCC6 Deficiency, and Calciphylaxis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Inozyme Pharma
NGM Bio
HQ: United States
Website
- Description: Provider of biotherapeutic drug discovery focused on the gastrointestinal endocrine system, developing: NGM707 (ILT2/ILT4 antagonist), NGM831 (ILT3 antagonist), NGM438 (LAIR1 antagonist) for advanced solid tumors; NGM120 (GFRAL antagonist) for advanced solid tumors and cachexia; NGM621 (anti-Complement C3) for geographic atrophy; aldafermin (FGF19 analog) for NASH F4 and primary sclerosing cholangitis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NGM Bio company profile →
Humedics
HQ: Germany
Website
- Description: Provider of rapid, precise liver function measurement via LiMAx, an easy-to-use bedside, non-invasive breath analysis test using 13C-labelled methacetin to assess liver function capacity. Offers LiMAx device development for surgical use with potential expansion into general healthcare, and supports investigator-initiated research. Applications include planning liver surgeries, patient selection, postoperative management, and assessing disease severity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Humedics company profile →
89bio
HQ: United States
Website
- Description: Provider of biologic and small molecule therapies for liver and metabolic disorders, developing pegozafermin for MASH to reduce liver fibrosis and for severe hypertriglyceridemia to lower triglyceride levels and address lipid metabolism imbalance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 89bio company profile →
PhaseBio
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical drug development targeting cardiovascular, endocrine, and metabolic disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PhaseBio company profile →
Ocera Therapeutics
HQ: United States
Website
- Description: Provider of novel therapeutics in development for patients with acute and chronic liver disease, as a clinical-stage biopharmaceutical company focused on development and commercialization in an area of high unmet medical need; HE clinical development includes a recently completed Phase 2b trial, STOP-HE, which evaluated safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ocera Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Inozyme Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Inozyme Pharma
2.2 - Growth funds investing in similar companies to Inozyme Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Inozyme Pharma
4.2 - Public trading comparable groups for Inozyme Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →